Key result
This review summarizes recent advances in the epidemiology, genetics, pathophysiological mechanisms, and management of atrial fibrillation, including antiarrhythmic drugs and ablation.
Why the study?
The molecular and cellular mechanisms underlying AF remain incompletely established, while current antiarrhythmic drugs carry significant adverse events and ablation management is suboptimal.
This review provides an overview of the current understanding of atrial fibrillation mechanisms and the status of its management through drugs and ablation.
No takes yet. Share an insight, caveat, or question.
Current AF therapies retain key limitations; leaves open mechanism-driven treatment development for clinicians and researchers.
Hu et al. (2023) conducted a review in Atrial fibrillation. This review summarizes recent advances in the epidemiology, genetics, pathophysiological mechanisms, and management of atrial fibrillation, including antiarrhythmic drugs and ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: